Exposure-response analyses of venetoclax combined with hypomethylating agents in myelodysplastic syndromes: a retrospective study.

ABSTRACT:

Background

Venetoclax (VEN), an orally bioavailable B-cell lymphoma-2 inhibitor, shows promising activity in patients with myelodysplastic syndromes (MDS) when combined with hypomethylating agents (HMAs). However, research regarding the VEN exposure in Chinese patients with MDS remains notably sparse.

Methods

This study retrospectively collected the predose (C₀) and 6 h post-oral dosing plasma concentration (C₆) of VEN for exposure-response analyses, using graphical analysis, receiver operator characteristic (ROC) curves, and logistic regression. Sixty-four patients were included in the exposure-safety analyses. Thirty-nine patients who were treated with HMAs as first-line treatment and added VEN within 4 cycles, or received VEN + HMAs as the initial tr

SUBMITTER: Tian JX 

PROVIDER: S-EPMC12301662 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature